A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)

Trial Profile

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; B cell lymphoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ECHO-202; KEYNOTE-037
  • Sponsors Incyte Corporation; Merck & Co
  • Most Recent Events

    • 12 Sep 2017 Results (data cut off: 27 Feb 2017, n=64) assessing efficacy and safety of epacadostat plus pembrolizumab in patients with advanced melanoma, presented at the 42nd European Society for Medical Oncology Congress
    • 09 Sep 2017 According to an Incyte Corporation Media Release, results from this study will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress
    • 09 Sep 2017 Results published in an Incyte Corporation Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top